As Fate Therapeutics INC (FATE) Market Valuation Rose, Holder Artal Group Sa Cut Stake by $5.95 Million

Investors sentiment decreased to 1.08 in Q1 2019. Its down 0.52, from 1.6 in 2018Q4. It dropped, as 11 investors sold FATE shares while 39 reduced holdings. 20 funds opened positions while 34 raised stakes. 55.48 million shares or 3.48% more from 53.61 million shares in 2018Q4 were reported. 20,000 were accumulated by Baker Avenue Asset Ltd Partnership. Tiaa Cref Invest Mngmt Ltd Liability Company accumulated 99,950 shares or 0% of the stock. First Mercantile Trust has invested 0.06% in Fate Therapeutics, Inc. (NASDAQ:FATE). State Farm Mutual Automobile Insurance Com stated it has 28,144 shares or 0% of all its holdings. Goldman Sachs owns 378,850 shares. Aqr Management Lc stated it has 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Alpinvest Prtnrs Bv reported 0.5% stake. Ameritas Investment Partners holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 5,030 shares. Rhumbline Advisers holds 80,220 shares. Citadel Advsr Limited Co holds 0.01% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 869,789 shares. Wells Fargo Mn holds 0% or 140,885 shares in its portfolio. Blume Cap owns 600 shares. Pnc Fincl Svcs Grp holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 10,860 shares. Citigroup holds 0% or 17,330 shares in its portfolio. First Republic Investment Mgmt reported 37,632 shares or 0% of all its holdings.

Artal Group Sa decreased its stake in Fate Therapeutics Inc (FATE) by 16.28% based on its latest 2019Q1 regulatory filing with the SEC. Artal Group Sa sold 350,000 shares as the company’s stock rose 35.11% . The institutional investor held 1.80M shares of the health care company at the end of 2019Q1, valued at $31.63M, down from 2.15M at the end of the previous reported quarter. Artal Group Sa who had been investing in Fate Therapeutics Inc for a number of months, seems to be less bullish one the $1.15 billion market cap company. The stock decreased 1.62% or $0.29 during the last trading session, reaching $17.59. About 443,930 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 152.00% since August 15, 2018 and is uptrending. It has outperformed by 152.00% the S&P500.

Artal Group Sa, which manages about $2.45 billion US Long portfolio, upped its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) by 150,000 shares to 450,000 shares, valued at $42.05M in 2019Q1, according to the filing. It also increased its holding in Bristol Myers Squibb Co (Call) (NYSE:BMY) by 100,000 shares in the quarter, for a total of 650,000 shares, and has risen its stake in Tg Therapeutics Inc (NASDAQ:TGTX).

More notable recent Fate Therapeutics, Inc. (NASDAQ:FATE) news were published by: Finance.Yahoo.com which released: “What You Must Know About Fate Therapeutics, Inc.’s (NASDAQ:FATE) Beta Value – Yahoo Finance” on May 29, 2019, also Finance.Yahoo.com with their article: “Steven Cohen Charges Into Chiasma – Yahoo Finance” published on July 31, 2019, Nasdaq.com published: “Factors Likely to Decide JD.com’s (JD) Fate in Q1 Earnings – Nasdaq” on May 08, 2019. More interesting news about Fate Therapeutics, Inc. (NASDAQ:FATE) were released by: Nasdaq.com and their article: “Interesting FATE Put And Call Options For July 19th – Nasdaq” published on May 21, 2019 as well as Streetinsider.com‘s news article titled: “Fate Therapeutics (FATE) Granted Foundational US Patent Covering iPSC-derived CAR T Cells – StreetInsider.com” with publication date: August 14, 2019.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 4 analysts covering Fate Therapeutics (NASDAQ:FATE), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Fate Therapeutics has $2700 highest and $12 lowest target. $20.60’s average target is 17.11% above currents $17.59 stock price. Fate Therapeutics had 12 analyst reports since March 6, 2019 according to SRatingsIntel. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Hold” rating by H.C. Wainwright on Wednesday, March 6. On Wednesday, March 6 the stock rating was maintained by Wells Fargo with “Buy”.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.